A joint report by European science academies proposed regulatory sandboxes as controlled, time-limited environments to test medical artificial intelligence tools under regulatory oversight before clinical deployment.

Overview Debates Related claims Topics Sources

Inquiry chair Kate Lampard is considering issuing interim regulations and recommendations regarding Oxevision camera technology to prevent further avoidable patient deaths.

In 2021, NHS England raised serious patient safety concerns regarding Oxevision's usage and capability claims with the Medicines and Healthcare products Regulatory Agency.

The Medicines and Healthcare products Regulatory Agency requested clinical evidence from manufacturer Lio Health supporting claims that Oxevision reduced self-harm, but Lio Health failed to provide it.

Lawyers representing over 70 bereaved families urged the Lampard Inquiry on October 20, 2026 to recommend a national ban on Oxevision in NHS mental health inpatient wards.

NHS England stated that legal and operational responsibility for deploying and operating the Oxevision camera system rests entirely with individual NHS foundation trusts.

False pulse readings produced by the Oxevision patient monitoring system were reported to the British Standards Institution in 2023.

India's Ministry of Health launched the Strategy for Artificial Intelligence in Healthcare for India in February 2026 to govern data, validation, deployment, and monitoring.

India's Central Drugs Standard Control Organisation requires artificial intelligence developers to demonstrate clinical validity, demographic diversity in training datasets, version control, and post-market surveillance plans.

A report by the European Academies Science Advisory Council and the Federation of European Academies of Medicine recommended that high-risk artificial intelligence systems in healthcare remain under strict human supervision.

India's Central Drugs Standard Control Organisation issued guidance in July 2026 establishing approval pathways for Software in a Medical Device and Software as a Medical Device.

Regulatory sandboxes allow health authorities to evaluate rapidly evolving artificial intelligence technologies and balance patient safety against clinical innovation.

Sound Practice 10 of the Financial Stability Board's guidance establishes a risk-based intervention model requiring mandatory human sign-off for financial transactions exceeding specific thresholds.

The Financial Stability Board published 12 non-binding recommended practices on October 16, 2026, for the responsible adoption of artificial intelligence in financial institutions across G20 economies.

Bank of England Governor Andrew Bailey proposed pre- and post-deployment testing protocols for frontier AI models used in finance and G20-level agreements governing access to foreign-built frontier models.

The OCC, Federal Reserve Board, and FDIC plan a future request for information regarding bank AI model risk management, though no timeline has been set.

US regulatory guidance OCC Bulletin 2026-13, issued jointly by the OCC, Federal Reserve Board, and FDIC on April 17, 2026, explicitly excluded generative and agentic AI models from its scope.

Sound Practice 12 expects financial institutions to secure contractual rights covering audit access, data portability, security incident notification, and orderly service termination before deploying externally sourced AI systems.

The American Medical Association's framework focuses on four questions covering clinical functions, evidence of performance, conditions of permission, and risk accountability.

The Financial Stability Board declined to framing AI systems as synthetic employees, citing concerns that the analogy obscures unpredictable autonomous decisions.

Updated Sound Practice 12 requires financial institutions to perform due diligence and maintain ongoing oversight of embedded AI functionality extending to fourth- and nth-party vendors.